Safura Abdool Karim, Ruth R. Faden, Chloe Searchinger, Thomas J. Bollyky
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
World Health Organization guideline on the use and indications of glucagon-like peptide-1 therapies for the treatment of obesity in adults.
10.1001/jama.2025.24288 · 2026
FDA approves GLP-1 pill for cardiovascular risk in type 2 diabetes.
10.1001/jama.2025.19724 · 2025
Patents and regulatory exclusivities on GLP-1 receptor agonists.
10.1001/jama.2023.13872 · 2023
Estimated sustainable cost-based prices for diabetes medicines.
10.1001/jamanetworkopen.2024.3474 · 2024
Online prescribing of GLP-1 receptor agonists.
10.1001/jama.2026.9131 · 2026
Availability and affordability of medicines for diabetes and cardiovascular disease across countries: information learned from the Prospective Urban Rural Epidemiological Study.
10.3390/diabetology3010014 · 2022
Twenty years of antiretroviral therapy for people living with HIV: global costs, health achievements, economic benefits.
10.1377/hlthaff.2018.05391 · 2019
The concept of access: definition and relationship to consumer satisfaction.
10.1097/00005650-198102000-00001 · 1981
Global, regional, and national prevalence of adult overweight and obesity, 1990-2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021.
10.1016/s0140-6736(25)00355-1 · 2025
The benefits of GLP-1 drugs beyond obesity.
10.1126/science.adn4128 · 2024
Driving a decade of change: HIV/AIDS, patents and access to medicines for all.
10.1186/1758-2652-14-15 · 2011
Access to drugs for treatment of noncommunicable diseases.
10.1371/journal.pmed.1001485 · 2013
International coverage of GLP-1 receptor agonists: a review and ethical analysis of discordant approaches.
10.1016/s0140-6736(24)01356-4 · 2024
Essential medicines for cancer: WHO recommendations and national priorities.
10.2471/blt.15.163998 · 2016
Metabolic rebound after GLP-1 receptor agonist discontinuation: a systematic review and meta-analysis.
10.1016/j.eclinm.2025.103680 · 2025
GLP-1 receptor agonists for obesity: eligibility across 99 countries.
10.1016/s2213-8587(25)00356-0 · 2026
A systematic review of task-shifting for HIV treatment and care in Africa.
10.1186/1478-4491-8-8 · 2010
The global syndemic of obesity, undernutrition, and climate change: the Lancet Commission report.
10.1016/s0140-6736(18)32822-8 · 2019
The challenge for global health systems in preventing and managing obesity.
10.1111/obr.12872 · 2019
What is the role of primary prevention of obesity in an age of effective pharmaceuticals?
10.1007/s13679-025-00632-0 · 2025
Unresolved referenced work
2017
Unresolved referenced work
2024
Unresolved referenced work
Kept as external metadata until matched
Unresolved referenced work
Kept as external metadata until matched
10.1101/2024.11.11.24317112
10.1101/2024.11.11.24317112
No additional external references are available.
